Shares Rise 4.47% After Treace Medical Q1 Revenue $47.2M, EPS Loss –$0.28
TMCI•Treace Medical Concepts posted Q1 revenue of $47.20 million, surpassing consensus of $45.96 million, and delivered EPS of –$0.28 versus –$0.31 forecast. Shares jumped 4.47% on volume of 239,162, lifting market capitalization to $129.95 million while trading near its 52-week low of $1.17 within a $1.17–$7.78 range.
1. Q1 Financial Results
Treace Medical Concepts reported revenue of $47.20 million for the quarter, exceeding the $45.96 million consensus. The company delivered an EPS loss of –$0.28, outperforming the –$0.31 per share estimate, marking its second consecutive quarter of narrowed losses.
2. Market Reaction
Following the earnings release, shares climbed 4.47%, with trading volume reaching 239,162 shares. This lifted Treace Medical’s market capitalization to $129.95 million, although the stock remains near its 52-week low of $1.17 within a trading range of $1.17 to $7.78.
3. Product Focus
Treace Medical Concepts specializes in innovative foot and ankle surgical solutions, notably its Lapiplasty System for bunion correction. The technology aims to improve patient outcomes by addressing the root cause of bunion deformities compared to traditional methods.
